[This Week's IPO] Demand Forecasting and Subscription Schedule for the Fourth Week of February

In the fourth week of this month (February), Kana Therapeutics and IM Biologics will conduct book building (institutional demand forecasting). Esteem and Axvis are preparing for their public subscription.

<Book Building (Institutional Demand Forecasting)>

◆ Kana Therapeutics = Established in February 2019, Kana Therapeutics is developing innovative new drugs using human genome-based drug development technology. In particular, the company is continuously expanding its pipeline to address the unmet medical needs of solid cancer patients through bispecific antibody-based immuno-oncology drugs based on mechanisms targeting the tumor microenvironment and immune activation modulation technology, as well as ADC therapies utilizing next-generation ADC technology.

The company plans to offer a total of 2 million shares to the public, with an indicative price range of 16,000 to 20,000 won, for an expected offering size of 32 billion to 40 billion won. It will conduct book building from February 23 to 27 and accept subscriptions on March 5 to 6. The lead manager is Korea Investment & Securities.

◆ IM Biologics = Founded in 2020, IM Biologics is an antibody new drug development company targeting autoimmune diseases. Recognized for the value of its pipeline based on an original platform technology, it passed the technology evaluation threshold in July last year by receiving A and A grades from two specialized evaluation agencies.

The company will offer a total of 2 million shares. The indicative price range is 19,000 to 26,000 won. It will carry out book building from February 27 to March 6 and then accept subscriptions on March 11 to 12. The lead managers are Korea Investment & Securities and Shinhan Investment & Securities.

<Public Subscription for Retail Investors>

◆ Esteem = The offering price has been set at 8,500 won, the top end of the indicative range. The institutional book-building competition rate reached 1,335 to 1. After public subscription for retail investors on February 23 to 24, the company is scheduled to list on the KOSDAQ market on March 6. The lead manager is Korea Investment & Securities.

Esteem operates brand marketing and content businesses based on the IP of exclusive models and influencers. It produces a variety of content such as promotional videos, fashion shows, and pop-up stores that reflect trends across the fashion industry.

◆ Axvis = The offering price has been set at 11,500 won, the upper end of the indicative range. In the book building, the competition rate reached 1,124.21 to 1. After a two-day public subscription for retail investors on February 23 to 24, the company is scheduled to list on the KOSDAQ market on March 9. The lead manager for the listing is Mirae Asset Securities.

Founded in 2009, Axvis is a specialized provider of laser processing solutions used in advanced product manufacturing processes. The company owns VisionSCAN, Korea's first intelligent high-power laser platform that combines AI and robotics technologies. VisionSCAN is evaluated as having differentiated competitiveness by simultaneously achieving high quality and maximized productivity through three key features: enabling high-speed processing, AI-based high-precision control, and minimizing process cycle time based on robotics.